Nascent Biotech Inc Completes $740,000 Equity Round of Funding
SAN DIEGO, CA / ACCESSWIRE / August 24, 2020 / Nascent Biotech, Inc (OTCQB:NBIO) announced today that it is closing on a direct private placement with aggregate proceeds of $740,000.
The proceeds allow the Company to complete the required testing for removing the partial clinical trial hold, imposed by the FDA, and will permit the company to begin the Phase I clinical trials on brain cancer.
Sean Carrick, CEO of Nascent commented, “The financing has come from private individual investors and we are pleased by the interest in this round. We chose to accept strategic money knowing equity funding will prove to be more beneficial to the Company than debt financing.”
About Nascent Biotech, Inc.:
Nascent Biotech, Inc. is a clinical-stage biotech company pioneering the development of monoclonal antibodies (mAbs) for the treatment of incurable cancers such as brain and pancreas, as well as hard-to-treat cancers such as colon and lung. Nascent is also employing its mAbs as part of treatments for dangerous viral infections, such as COVID-19. Collectively, cancers and viral infections afflict and kill tens of millions worldwide each year. Nascent’s products are not commercially available. Our lead candidate, Pritumumab (PTB), is a fully human mAb that will commence study in an FDA-approved Phase I clinical trial later this year for the treatment of primary and metastatic brain cancer, including glioblastoma and malignant astrocytoma. Development of PTB as a potential treatment for COVID-19 has been initiated. For more information, visit www.nascenbiotech.com.
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
President | CEO
Nascent Biotech, Inc.
6330 Nancy Ridge Dr
San Diego CA 92121